Value of glypican 3, Hep Par and alpha fetoprotein in diagnosis of hepatocellular carcinoma N. Gursan * , H. Balta, B. Gundogdu * Ataturk University, Medical Faculty, Erzurum, Turkey Objective: Glypican 3 showed high expression of the embryonic liver and intestine, is silenced in normal adult tissues. It is an oncofetal protein. İn general, oncofetal proteins, while having a critical role in tumor progression or immunotherapy is a potent tumor marker used as a target. Alpha fetoprotein, clone C3 localized, normally produced by gestational age, fetal liver and yolc salc, glycoprotein structure emerging marker for patients with HCC. Hep Par 1 antibody was developed in 1993 using fixed liver as immunogen. Method: İn this study formalin-fixed, paraffin-embedded surgical specimens from 20 patients with hepatocellular carcinoma diagnosed between 2000 and 2011 years in Ataturk University, Faculty of Medicine Department of pathology were studied with immunohistochemistry GPC3, Heppar 1, and AFP. GPC3, Heppar 1 and AFP expression was divided into 2 categories negative (negative or weak under %5 tumor cells cytoplasmic staining) and positive (and %5 over of tumour cells) moderate or strong cytoplasmic with membranous accentuation. Results: Immunpositivity at GPC3, Hep Par 1 and AFP were 85 %, 95 %, 75 % respectively. Objective: Fibroblastic growth factor receptor (FGFR) family is known to be related to the development and progression of various types of cancers. The aim of this study is to determine the clinical implication of FGFR expressions in patients with hepatocellular carcinoma (HCC). Method: Immunohistochemical analysis was done in 842 cases of HCC using tissue microarray. Diffuse cytoplasmic staining for FGFR1, 2, 3 and 4 in more than 10 % of tumor cells were designated as positive. The results were analyzed in terms of various clinicopathologic parameters. Results: On univariate analysis, the overall survival rates of patients with FGFR2 expression (152 cases, 18.1 %) were significantly lower than those with no expression (HR 1.838, 95 % CI 1.452-2.328, P<0.001). However, the overall survival rates of patients with FGFR4 expression (446 cases, 59.6 %) were significantly higher than those with no expression (HR 0.636, 95 % CI 0.521-0.776, P<0.001). There was no statistical significance between patients' overall survival rates and expressions of FGFR1 (46 cases, 5.5 %) or FGFR3 (33cases, 4.0 %). On multivariate analysis, only FGFR2 expression is independently associated with reduced OS (FGFR2: HR 1.790, 95 % CI 1.404-2.282, P<0.001). Conclusion: The FGFR2 expression can be used as an independent prognostic factor in patients with surgically resected HCC. Objective: HURP (hepatoma upregulated protein) is a putative oncogene, overexpressed in many human cancers, including hepatocellular carcinoma. It has also been shown recently that high HURP protein levels correlate with resistance to chemotherapeutic agents. In the present study we investigate the expression of HURP and its correlation with pancreatic adenocarcinoma, prognosis and patient survival. Pancreatic adenocarcinoma is one of the most aggressive types of cancer and represents the fourth most common cause of death, either in the male or in the female population of the United States of America. Method: HURP immunoreactivity was assessed by immunohistochemistry in a series of 28 primary pancreatic adenocarcinomas. In parallel, HURP expression was examined in 10 normal pancreatic tissues. Statistical analysis related HURP expression levels with clinicopathological characteristics and survival.